AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$53.12
neg -3.64
-6.41%
Today's Range: 52.62 - 56.34 | ABBV Avg Daily Volume: 8,787,500
Last Update: 02/05/16 - 4:00 PM EST
Volume: 13,123,276
YTD Performance: -4.19%
Open: $56.25
Previous Close: $56.76
52 Week Range: $45.45 - $71.60
Oustanding Shares: 1,634,746,917
Market Cap: 92,919,014,762
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 9 10
Moderate Buy 1 1 1 1
Hold 2 2 2 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.41 1.38 1.38 1.21
Latest Dividend: 0.57
Latest Dividend Yield: 4.01%
Dividend Ex-Date: 01/13/16
Price Earnings Ratio: 13.25
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
13.25 0.00 29.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-11.03% -0.26% 52.25%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $1.11 $1.22 $5.04 $5.98
Number of Analysts 5 3 9 8
High Estimate $1.15 $1.24 $5.10 $6.16
Low Estimate $1.03 $1.21 $4.95 $5.75
Prior Year $0.94 $1.08 $4.29 $5.04
Growth Rate (Year over Year) 18.09% 13.27% 17.46% 18.63%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Feb 5, 2016 | 11:38 AM EST
The market's major indices are getting worse as the morning progresses.
By

Bret Jensen

 | Feb 2, 2016 | 9:00 AM EST

In a year's time, investors may look back and think this was a great entry point.

By

Bret Jensen

 | Jan 26, 2016 | 10:00 AM EST

Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

By

Bret Jensen

 | Jan 19, 2016 | 10:00 AM EST

The year has not started the way most pundits and prognosticators had envisioned.

By

Bret Jensen

 | Jan 17, 2016 | 2:00 PM EST

Each of these small-caps delivered good news recently, only to have their stocks decline.

By

Bret Jensen

 | Jan 15, 2016 | 10:00 AM EST

Each of these small-caps delivered good news recently, only to have their stocks decline.

By

Bret Jensen

 | Jan 12, 2016 | 12:00 PM EST

It was all about the FANGs in 2015, but go for value plays this year.

By

Bret Jensen

 | Jan 5, 2016 | 9:00 AM EST

Look for market leadership to shift as the U.S. economy plods along.

By

Bret Jensen

 | Jan 4, 2016 | 11:00 AM EST

5 biotech stocks that could outperform the overall market in 2016.

By

Bret Jensen

 | Dec 31, 2015 | 10:00 AM EST

Don't catch falling knives, and don't ignore dividends.

The sharp decline in the index in the first half of January and then the reflexive bounce ...

Nice work on the diary today, Bret. Tough day but you killed it.

Tableau Software option trade opened yesterday on the PHLX stands out as a painful example...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.